Immunotherapy before eye removal for high-risk eye melanoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old
- You must have a type of eye melanoma called uveal melanoma that hasn’t spread or been treated yet
- You must be able to read and understand Danish
- You must be healthy enough for daily activities (ECOG score 0 or 1)
- Your liver and kidney function, blood counts must be within certain limits (checked with blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
This trial is for people with stage III melanoma that can be surgically removed. It compares one immunotherapy drug to a combination of two, to see which works better before surgery.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This study looks at how well immunotherapy works before surgery for melanoma that has spread. If you have stage III or IV melanoma that can be removed, you may be able to join this trial.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.